Lei Jianping on February 6
Lu Daopei Medical Group (hereinafter referred to as "Lu Daopei Medical") recently re-prospectused and updated its prospectus to prepare for listing on the Hong Kong Stock Exchange.
The 9-month revenue was 1.4 billion and the loss during the period was 88.03 million
Lu Daopei Medical has established a full-cycle hematology specialty service capability through various methods such as comprehensive hematopoietic stem cell transplantation, chemotherapy, targeting**, immunolunization and combination**, as well as providing hematology special examination services throughout the diagnosis and process.
According to the prospectus, Lu Daopei Medical's revenue in 2020, 2021, and 2022 will be 116.2 billion yuan, 13700 million yuan, 16$7.3 billion; Gross profit was 2400 million, 16.7 billion, 2$3.7 billion; The losses for the period were 12.2 billion yuan, 40.8 billion yuan, 54.7 billion yuan.
Lu Daopei Medical's revenue for the first nine months of 2023 was 14200 million yuan, and the revenue in the same period last year was 12400 million yuan; Gross profit is 18.8 billion yuan, compared with a gross profit of 23.4 billion yuan, gross profit in the same period last year was 1$8.8 billion; The loss for the period was 88.03 million yuan, compared with a loss of 5 in the same period last year1.2 billion yuan.
Lu Daopei Medical's adjusted EBITDA in 2020, 2021, and 2022 was 1., respectively900 million yuan, 76.09 million yuan, 1$4.5 billion; Lu Daopei Medical's adjusted EBITDA for the first nine months of 2023 was 1$3.5 billion, compared to an adjusted EBITDA of 1$2.8 billion.
Temasek and Jooin Capital are shareholders
The executive directors of Lu Daopei Medical are Dr. Lu Peihua, Ms. Zhao Yi, Dr. Lu Minggang and Ms. Wang Xiaowei; The non-executive directors are Ding Wei and Wang Wenhuai; The independent non-executive directors are Tan Bo, Yan Xiaowen and Li Jiacong.
Dr. Luk Pui-wah and Dr. Luk Ming-gang are cousins. Dr. Lu Peihua is the aunt of Lu Xiaodan, one of the controlling shareholders of the Company.
Dr. Luk Pui Wah, aged 66, is the Chairman of the Board and an Executive Director of the Company. He joined the Company in November 2015 and has served as the medical executive director of Hebei Yanda Lu Daopei Hospital and Beijing Lu Daopei Hospital Yizhuang Campus since November 2015 and a director of Lu Daopei Biotechnology from November 2017 to December 2018 and July 2020. He was appointed as a Director of the Company and was appointed as the Chairman of the Board on 5 October 2021 and was appointed as an Executive Director of the Company on 30 December 2022.
Dr. Lu Peihua is responsible for the overall strategic development of the Group, overseeing the hospital's medical operations and scientific research development, and participating in the decision-making of overall operation and management matters. She is the daughter of Academician Lu Daopei.
Lu Daopei, born in Shanghai in October 1931, is a Chinese hematologist and hematopoietic stem cell transplant expert, academician of the Chinese Academy of Engineering, and is also known as the first person in Asia to transplant bone marrow. In September 1981, after more than 50 days and nights of hard work by Lu Daopei's team, China's first allogeneic bone marrow transplant was declared successful.
From May 2015 to July 2016, as part of Academician Lu Daopei's succession plan and his semi-retirement status due to his age, Academician Lu Daopei gradually transferred his equity interest in the management of the hospital to his son Lu Wenzhao. A series of equity transfers immediately prior to the Track Record Period and as at 31 December 2019 through hospital management.
Temasek is a shareholder
Before Lu Daopei Medical submitted the prospectus, it sold old shares several times and raised funds three times, including 25.9 billion yuan, cost per share of 059 yuan, the company's post-investment valuation is 2$5.9 billion;
Lu Daopei Medical raised 35.8 billion, at a cost per share of 749 yuan, with a post-investment valuation of 36$3.3 billion; In 2020, it raised 1500 million yuan, cost per share of 99 yuan, with a post-investment valuation of 49500 million yuan.
As of the Latest Practicable Date, Lu Xiaodan controlled 3321% of the voting rights.
Therefore, as at the same date, Lu Xiaodan, Tyler Lu Limited and Hospital Management Holding were the controlling shareholders of Lu Daopei Medical.
Prior to the IPO, CBC Group entities held 1644%, Xiamen C&D entity holds 1127%, LDP New Hope holds 10% and Temasek holds 8% through Temasek SPV21%, and 594%, Qianhai Ark holds 519%；
Pagodatree** holds 22%, Investcorp SPV holds 205%, Sailing Capital holds 203%, 195%, Beijing Huiyu holds 051%；China Merchants ** holds 045%, Lin Rong holds 03%, and Beijing Yilu holds 015%, Partner Sky holds 009%。
Lei Di was founded by ** Lei Jianping, if ** please in**.